Full Press Release Details
OrthoPediatrics Corp. Announces Proposed
Public Offering of Common Stock
WARSAW, Indiana, June 17,
2020 - OrthoPediatrics Corp. ("OrthoPediatrics") (Nasdaq: KIDS), a company exclusively focused on advancing
the field of pediatric orthopedics, announced today that it is commencing an underwritten public offering of its common stock.
OrthoPediatrics intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public
offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
OrthoPediatrics intends to use the net
proceeds from the proposed offering to invest in implant and instrument sets for consignment to its customers, fund research and
development activities, and expand its sales and marketing programs, and for working capital and general corporate purposes.
Piper Sandler and Stifel are acting as
joint book-running managers of the proposed offering.
The proposed offering will be made pursuant
to a shelf registration statement on Form S-3 that became effective on March 27, 2020. The proposed offering will be
made only by means of a written prospectus and prospectus supplement that form part of the registration statement. A preliminary
prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC
and will be available on the SEC's website at www.sec.gov. When available, copies of the preliminary prospectus supplement
and accompanying prospectus may also be obtained for free from the offices of Piper Sandler & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at (800) 747-3924 or via email at prospectus@psc.com;
or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San
Francisco, CA 94104, via telephone at (415) 364-2720 or via email at syndprospectus@stifel.com.
This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.
Forward-Looking Statements
This press release includes "forward-looking
statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of
words such as "may," "might," "will," "should," "expect," "plan," "anticipate,"
"could," "believe," "estimate," "project," "target," "predict," "intend,"
"future," "goals," "potential," "objective," "would" and other similar expressions.
Forward-looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics' control. Important
factors could cause actual results to differ materially from those in the forward-looking statements, including, among others:
the risks related to COVID-19, the impact such pandemic may have on the demand for our products, and our ability to respond to
the related challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics'
Annual Report on Form 10-K filed with the SEC on March 5, 2020, as updated and supplemented by our other SEC reports
filed time to time. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to
update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such
statements except to the extent required by applicable securities laws.
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024